Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Towards A Unified Model Of RAF Inhibitor Resistance.

D. Solit, N. Rosen
Published 2014 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in patients with BRAF-mutant melanoma. Analysis of tumor samples collected at the time of disease progression indicates that alterations within the extracellular signal-regulated kinase (ERK) pathway that result in reactivation of ERK signaling are present in most patients. Mutations in the phosphoinositide 3-kinase/AKT pathway that enhance the adaptive response to RAF inhibitors also contribute to RAF inhibitor resistance in a subset of patients.
This paper references
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
E. Romano (2013)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
F. Xing (2012)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
E. V. Van Allen (2014)
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
N. Wagle (2014)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G. Bollag (2010)
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
S. Whittaker (2013)
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
R. Corcoran (2010)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.
H. Shi (2014)
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
BRAF mutation predicts sensitivity to MEK inhibition
D. Solit (2006)
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
H. Shi (2014)
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Piro Lito (2012)
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle (2011)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
M. D. Thakur (2013)
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)

This paper is referenced by
Systematic analysis of BRAFV 600 E melanomas reveals a role for JNK / c-Jun pathway in adaptive resistance to drug-induced apoptosis
M. Fallahi-Sichani (2015)
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma*
Bingying Zhou (2016)
Melanoma Therapeutic St rategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence Graphical
K. R. Singleton (2017)
Anaphase-Promoting Complex Adaptor FZR1/CDH1 Blocks BRAF Signaling Both by Targeting BRAF for Proteolytic Degradation and by Disrupting BRAF Dimerization.
C. Zhang (2017)
Supplementary Issue: Breast Cancer Detection and Screening
Xin Jin (2015)
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.
T. Horn (2016)
The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression
A. Shilo (2015)
Directly targeting transcriptional dysregulation in cancer
T. Gonda (2015)
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
K. R. Singleton (2017)
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
C. P. Prasad (2015)
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression
Berline Murekatete (2017)
Targeting Breast Cancer Metastasis
Xin Jin (2015)
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
Jin He Wang (2015)
Can the Dual Inhibition of Extracellular Signal-Related Kinase (ERK) and Phosphoinositide-3 Kinase (PI3K) Increase Efficacy of Cisplatin in Endometrial and Ovarian Cancers?
H. G. Schoch (2016)
Chapter 8 Emerging Drug Combination Approaches in Melanoma Therapy
J. Wang (2018)
Anomalies moléculaires de la voie MAPK et cancer papillaire de la thyroïde : étude de deux phosphatases spécifiques de ERK, DUSP5 et DUSP6
C. Buffet (2014)
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Jia-Ren Lin (2015)
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
A. Gunderwala (2019)
RAS signaling and therapeutic resistance in melanoma
Bingying Zhou (2016)
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
Roei D Mazor (2020)
Principles of Targeted Therapy
Gideon Bollag (2018)
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
Devin G. Roller (2016)
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
Lixin Wan (2017)
Emerging Drug Combination Approaches in Melanoma Therapy
J. Wang (2015)
Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis
M. Fallahi-Sichani (2015)
BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
K. Kemper (2016)
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy
J. Belizário (2016)
Rational Cancer Treatment Combinations: An Urgent Clinical Need.
J. Boshuizen (2020)
Mapping the Pathways of Resistance to Targeted Therapies.
K. Wood (2015)
The landscape of BRAF transcript and protein variants in human cancer
Andrea Marranci (2017)
Braf V600e Kinase Domain Duplication Identified in Therapy-refractory Melanoma Patient-derived Xenografts Resource Braf V600e Kinase Domain Duplication Identified in Therapy-refractory Melanoma Patient-derived Xenografts
Kristel Kemper ()
Resource BRAFV 600 E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts Graphical
K. Kemper ()
See more
Semantic Scholar Logo Some data provided by SemanticScholar